recommendations for Nunavik to provide chemoprophylaxis to household and other close contacts of children with HiA infection (10) , as was used for HiB (14) . Final data for the region for 2014 and 2015 are not available; however, since November 2013, there has been only one case of HiA infection transferred to Montreal Children's Hospital.
Information regarding rates of HiA carriage is sparse. Overall, rates of <1% to 3.5% for children have been reported from cities in Mexico and Brazil, and from an Aboriginal population in Australia (15) (16) (17) ; however, there are no data from North America. Studies involving a small number of close contacts of children with invasive HiA disease in Alaska reported carriage rates of 16% and 45% (11, 18) .
Serological studies involving Aboriginal adults in northern Ontario from 2010 to 2012 showed a high prevalence of anti-HiA antibodies with elevated immunoglobulin (Ig) M levels relative to IgG, whereas anti-HiB levels were lower and IgG predominated (19) . This suggested that HiA had only recently become widespread in the area, as reflected by the increase in reports of invasive HiA disease.
The pathogenicity and virulence of HiA are similar to that of HiB (20) , and the diseases it causes are similar (7). This may be explained by similar capsule structures and resistance to antibody-independant lysis by complement. The other four serotypes (C to F), which occur sporadically, are less virulent in animal models, have different capsule structures and are susceptible or less resistant to complement-mediated lysis (20) .
The HiA infection rate in young children in northern Canada is now above the rate observed in the general population when the HiB vaccine was introduced. Applying conjugates and methods used in the development of the HiB vaccine, the development of an HiA vaccine is technically feasible. To date, the population at risk is small and underprivileged. Production of an HiA vaccine for this group is unlikely to attract the attention of vaccine manufacturers. Individuals residing in Canada's north have unique health care needs that require government leadership and initiatives to ensure that they are met. To this end, a collaboration between the Public Health Agency of Canada, the National Research Council and the Northern Ontario School of Medicine launched a project in 2013, with the goal of developing a vaccine against HiA and a better understanding of HiA epidemiology through improved surveillance (21) .
The appropriate management of close contacts of HiA cases remains to be determined. Before the HiB vaccine became available, secondary cases occurred in 2% of household and 1% of day care contacts (14) . Chemoprophylaxis has been suggested for contacts of individuals with HiA (1,7,11), used by some (3, 10, 18) and discouraged by others because of an absence of data regarding carriage and efficacy (9, 22) . If carriage rates in close contacts are, in fact, in the range of 16% to 45%, it would be warranted. Studies investigating the effectiveness of HiA eradication using the antibiotic regimens used for HiB are needed. While awaiting further data and guidance, physicians and public health authorities will have to use judgement and knowledge of local epidemiology to decide whether prophylaxis is warranted.
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